Phio Pharmaceuticals ((PHIO)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Phio Pharmaceuticals is conducting a clinical study titled ‘Dose Escalation Study of Neoadjuvant Intratumoral PH-762 for Cutaneous Squamous Cell Carcinoma, Melanoma, or Merkel Cell Carcinoma’. The study aims to evaluate the safety and tolerability of PH-762, an RNAi molecule targeting PD-1, in treating specific skin cancers. This research is significant as it explores a novel treatment approach for these conditions.
The intervention being tested is PH-762, administered through intratumoral injections. This drug is designed to inhibit PD-1, potentially enhancing the immune response against tumors.
The study follows an interventional design with a single-group model. There is no masking involved, and the primary purpose is treatment. Participants will receive escalating doses of PH-762, with observations made between doses.
The study began on August 22, 2023, with an estimated primary completion date in 2025. The last update was submitted on July 28, 2025. These dates are crucial for tracking the study’s progress and potential data release.
This update could influence Phio Pharmaceuticals’ stock performance positively, as successful results may enhance investor confidence. The study’s progress could also impact competitors in the oncology sector, prompting further interest in RNAi-based therapies.
The study is ongoing, with further details available on the ClinicalTrials portal.